Popular Articles

PolyMedix Initiates Dosing In Second Phase I Clinical Study Of Novel Systemic Antibiotic Compound
PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, has initiated dosing in a second Phase I clinical trial with its defensin mimetic antibiotic compound, PMX-30063. PolyMedix received a notice of no objection from Health Canada for the Company"s Clinical Trial Application ("CTA") for PMX-30063 on May 21, 2009. PMX-30063 is a defensin mimetic antibiotic compound, the first of an entirely new class of antibiotic drugs that is believed to work in such a way that makes bacterial resistance unlikely to develop.

Medicaid Expansion: Health Care Reform's Newest Challenge
"Until the nation"s governors staged a public revolt last weekend, few people were paying attention to one of the most far-reaching proposals being considered as part of overhauling the health care system: a dramatic expansion and redefinition of the Medicaid program," Time reports. "Redefining who is eligible for Medicaid would be one of the major means by which lawmakers hope to achieve universal health coverage - which is one of the reasons that Governors, whose budgets already are straining under the program"s growing costs, are so wary of the idea."
News of the day
UCB Receives CHMP Positive Opinion On Bringing Neupro(R) Back To All Patients In Europe
UCB announced that the European Medicines Agency"s (EMEA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending that the European Commission lifts the treatment restrictions for Neupro® (rotigotine transdermal patch) in Europe.
Medical Devices

Celiac Disease Four Times More Common Than In 1950s

Celiac disease, an immune system reaction to gluten in the diet, is over four times more common today than it was 50 years ago, according to findings of a Mayo Clinic study published this month in the journal Gastroenterology. VIDEO ALERT: Additional audio and video res, including excerpts from an interview with Dr. Dr. Joseph Murray describing the research, are available on the Mayo Clinic News Blog. These materials are also subject to embargo, but may be accessed in advance by journalists for incorporation into stories. The password for this post is 0701Murray. The study also found that subjects who did not know they had celiac disease were nearly four times more likely than celiac-free subjects to have died during the 45 years of follow-up. "Celiac disease has become much more common in the last 50 years, and we don"t know why," says Joseph Murray, M.D., (http://www.mayoclinic.org/bio/13032852.html) the Mayo Clinic gastroenterologist who led the study. "It now affects about one in a hundred people. We also have shown that undiagnosed or "silent" celiac disease may have a significant impact on survival. The increasing prevalence, combined with the mortality impact, suggests celiac disease could be a significant public health issue." In patients with celiac disease, the presence of a protein called gluten from wheat, barley or rye triggers an immune system attack, damaging the villi in the small intestine. Villi are fingerlike projections that increase the intestine"s surface area for nutrient absorption. Celiac disease symptoms may include diarrhea, abdominal discomfort, weight loss, anemia, unexplained infertility, loss of teeth or even premature or severe osteoporosis. The Mayo Clinic research team tested blood samples gathered at Warren Air Force Base (AFB) in Wyoming between 1948 and 1954 for the antibody that people with celiac disease produce in reaction to gluten. They compared those blood test results with those from two recently collected sets from Olmsted County, Minn. One matched the ages of those from the 1948-1954 testing at the time of the blood draw, and the other matched their birth years. Researchers found that young people today are 4.5 times more likely to have celiac disease than young people were in the 1950s, while those whose birth years matched the Warren AFB participants were four times more likely to have celiac disease. "Celiac disease is unusual, but it"s no longer rare," says Dr. Murray. "Something has changed in our environment to make it much more common. Until recently, the standard approach to finding celiac disease has been to wait for people to complain of symptoms and to come to the doctor for investigation. This study suggests that we may need to consider looking for celiac disease in the general population, more like we do in testing for cholesterol or blood pressure." Dr. Murray says the study findings highlight the need for increased awareness of celiac disease, both among physicians and patients. "Part of the problem is that celiac disease symptoms are variable and can be mistaken for other diseases that are more common, such as irritable bowel syndrome," he says. "Some studies have suggested that for every person who has been diagnosed with celiac disease, there are likely 30 who have it but are not diagnosed. And given the nearly quadrupled mortality risk for silent celiac disease we have shown in our study, getting more patients and health professionals to consider the possibility of celiac disease is important." In addition to Dr. Murray, authors of the study, which was conducted in collaboration with the University of Minnesota Medical School and the Medical Follow-Up Agency, Washington, D.C., include Alberto Rubio Tapia, M.D.; Robert Kyle, M.D.; Edward Kaplan, M.D.; Dwight Johnson; William Page, Ph.D.; Frederick Erdtmann, M.D.; Tricia Brantner; W. Ray Kim, M.D.; Tara Phelps; Brian Lahr; Alan Zinsmeister, Ph.D.; and L. Joseph Melton III, M.D. Mayo Clinic


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):